In Japan, the medicine was launched at $35,000 in present day U.S. dollars, Mitsubishi Tanabe said in a statement. The drug is indicated for all ALS patients, without a restriction. In 2006, Hiide Yoshino, a neurologist at Khodani Hospital in Japan, published a study in the scientific journal ALS that seemed to suggest the drug might help ALS patients. If Radicat does the same -- three months, four months, five months -- and it costs somebody $300,000 to get those five months, that’s a hard discussion." Another issue, Staff says, is that, as with Riluzole, the drug slows a patient's decline but does not stop it.

Source: Forbes May 05, 2017 23:00 UTC